Literature DB >> 15540402

Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?

Megan E Coombes1, Steven G Morgan, Morris L Barer, Nino Pagliccia.   

Abstract

BACKGROUND: Public prescription drug plans vary markedly across Canada. To address perceived inequities in coverage across provinces, the February 2003 First Ministers' Accord on Health Care Renewal committed to ensuring that all Canadians have reasonable access to catastrophic drug coverage. A national standard for "reasonable" catastrophic coverage has yet to be formally defined.
OBJECTIVE: To compare the private financial burdens from prescription drugs that Canadian households would face if each of the current provincial pharmacare models were adopted as the national standard.
METHODS: Through simulation modelling, we computed household private financial burden by applying the cost-sharing rules from provincial drug plans to a nationally representative set of 4,860 household types differing in size, age composition, income and drug expense levels. The proportions of households that would face private out-of-pocket payments exceeding critical, or catastrophic, percentages of household income were calculated.
RESULTS: Private financial burden due to prescription drug costs varies considerably across provincial pharmacare models. Comprehensive, tax-financed pharmacare models that limit out-of-pocket expenditures to a given percentage of income, such as those found in British Columbia, Saskatchewan, Manitoba and Ontario, provide the greatest protection against catastrophic prescription drug costs. There appears, however, to be no "gold standard" for an acceptable financial burden to be borne by patients.

Entities:  

Mesh:

Year:  2004        PMID: 15540402     DOI: 10.12927/hcq.2004.17236

Source DB:  PubMed          Journal:  Healthc Q        ISSN: 1710-2774


  8 in total

1.  The born identity: prescription drug coverage by eligibility group.

Authors:  Fok-Han Leung; Rachael Frankford
Journal:  Can Fam Physician       Date:  2011-09       Impact factor: 3.275

2.  The financial burden of out of pocket prescription drug expenses in Canada.

Authors:  Sam Caldbick; Xiaojing Wu; Tom Lynch; Naser Al-Khatib; Mustafa Andkhoie; Marwa Farag
Journal:  Int J Health Econ Manag       Date:  2015-03-24

3.  Coping strategies used by patients infected with hepatitis C virus who are facing medication costs.

Authors:  Chiranjeev Sanyal; Ethel Langille Ingram; Ingrid S Sketris; Kevork M Peltekian; Susan Kirkland
Journal:  Can J Hosp Pharm       Date:  2011-03

4.  Comparison of Canadian public medication insurance plans and the impact on out-of-pocket costs.

Authors:  David J T Campbell; Braden J Manns; Lesley J J Soril; Fiona Clement
Journal:  CMAJ Open       Date:  2017-11-22

5.  Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.

Authors:  Haroon Hasan; Fuchsia Howard; Steven G Morgan; Daniel L Metzger; Andrea C Lo; Karen Goddard; Sabrina Gill; Michelle Johnson
Journal:  Healthc Policy       Date:  2014-02

6.  Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.

Authors:  Virginie Demers; Magda Melo; Cynthia Jackevicius; Jafna Cox; Dimitri Kalavrouziotis; Stéphane Rinfret; Karin H Humphries; Helen Johansen; Jack V Tu; Louise Pilote
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

7.  Income-based drug coverage in british columbia: towards an understanding of the policy.

Authors:  Steve Morgan; Megan Coombes
Journal:  Healthc Policy       Date:  2006-11

8.  Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.

Authors:  Logan McLeod; Basil G Bereza; Minsup Shim; Paul Grootendorst
Journal:  Open Med       Date:  2011-01-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.